An evaluation of cephradine oral suspension in the treatment of bacterial infections of infants and children.
D000284:Administration, Oral; D001424:Bacterial Infections / Q000188:drug therapy*; D002506:Cephalexin / Q000008:administration & dosage; D002511:Cephalosporins / Q000008:administration & dosage*; D002515:Cephradine / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003872:Dermatitis / Q000188:drug therapy; D004311:Double-Blind Method; D004927:Escherichia coli Infections / Q000188:drug therapy; D005260:Female; D006192:Haemophilus Infections / Q000188:drug therapy; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D011008:Pneumococcal Infections / Q000188:drug therapy; D011512:Proteus Infections / Q000188:drug therapy; D012141:Respiratory Tract Infections / Q000188:drug therapy; D013203:Staphylococcal Infections / Q000188:drug therapy; D013290:Streptococcal Infections / Q000188:drug therapy; D013297:Streptococcus pyogenes; D014552:Urinary Tract Infections / Q000188:drug therapy
D002511:Cephalosporins; D002515:Cephradine; D002506:Cephalexin